Amylou Dueck, Ph.D.
Affiliations: | 2005 | Arizona State University, Tempe, AZ, United States |
Area:
StatisticsGoogle:
"Amylou Dueck"Parents
Sign in to add mentorSharon Lohr | grad student | 2005 | Arizona State | |
(Robust imputation in multivariate hierarchical data.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Eiger D, Pondé NF, Agbor-Tarh D, et al. (2020) Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer |
Taarnhøj GA, Johansen C, Lindberg H, et al. (2020) Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Medicine |
Huberty J, Eckert R, Dueck A, et al. (2019) Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. Bmc Complementary and Alternative Medicine. 19: 121 |
Mascarenhas J, Lu M, Kosiorek H, et al. (2019) Oral Idasanutlin in Patients with Polycythemia Vera. Blood |
Solinas C, Silva PD, Venet D, et al. (2019) Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial Cancer Research. 79: 3132-3132 |
Macarulla Mercade T, Hendifar A, Li CP, et al. (2018) Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii253 |
Padrnos L, Ernst B, Dueck AC, et al. (2018) A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma & Leukemia |
Chumsri S, Sperinde J, Liu H, et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Sonbol MB, Hilal T, Dueck AC, et al. (2018) A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia & Lymphoma. 1-7 |
Gowin K, Kosiorek H, Dueck A, et al. (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia Research. 60: 31-35 |